Table 4. Association with CYP2E1 RsaI/PstI polymorphism and progression of gastric cancer.

	Total	C1C1		C1C2		C2C2
	No.	No.	%	No.	%	No.	%
Tumor stage
I	41	30	73.2	9	21.9	2	4.9
II	181	128	70.7	45	24.9	8	4.4
III	162	93	57.4	51	31.5	18	11.1
IV	25	8	32.0	11	44.0	6	24.0
Adjusteda OR (95% CI)
III vs. I		1.00		2.29 (0.94–5.58)		5.17 (1.05–25.54)
III+ IV vs. I		1.00		2.30 (0.98–5.38)		4.80 (1.03–22.45)
III+ IV vs. I+ II		1.00		1.89 (1.18–3.03)		4.38 (1.92–9.97)
Tumor grade
Low	56	39	69.6	13	23.2	4	7.1
Intermediate	116	79	68.1	20	17.2	17	14.7
High	231	152	65.8	67	20.3	12	5.2
Adjusteda OR (95% CI)
Intermediate vs. Low		1.00		0.59 (0.26–1.35)		1.88 (0.58–6.14)
High vs. Low		1.00		0.50 (0.20–1.26)		0.65 (0.19–2.24)

^aAdjusted for sex, age and smoking habit.